Literature DB >> 9703163

Cognitive functioning after pallidotomy for refractory Parkinson's disease.

K Perrine1, M Dogali, E Fazzini, D Sterio, E Kolodny, D Eidelberg, O Devinsky, A Beric.   

Abstract

BACKGROUND: Earlier approaches to pallidotomy for refractory Parkinson's disease had significant complication rates. More recent approaches show fewer complications, but the effect of pallidotomy on cognition is unclear. The current study was conducted to examine the neuropsychological effects of unilateral pallidotomy.
METHODS: Neuropsychological testing was performed on patients with medically refractory, predominantly unilateral Parkinson's disease at baseline and after unilateral ventral pallidotomy (n=28) or after an equivalent period without surgery in control patients (n=10).
RESULTS: Pallidotomy patients showed no significant changes from baseline to retesting relative to the control group for any measure. Across all of the tests administered, only five of the surgery patients showed a significant decline, and of these five none declined on more than one test. Depression did not relate to preoperative or postoperative cognition. The pallidotomy group showed a significant improvement in motor functioning and activities of daily living whereas the control group did not. These measures were not associated with the neuropsychological test scores at baseline or retest.
CONCLUSIONS: Stereotactic unilateral ventral pallidotomy does not seem to produce dramatic cognitive declines in most patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703163      PMCID: PMC2170208          DOI: 10.1136/jnnp.65.2.150

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  39 in total

1.  Visual neglect in Parkinson's disease.

Authors:  C Villardita; P Smirni; G Zappalà
Journal:  Arch Neurol       Date:  1983-11

2.  Parkinsonian dementia: cortical or subcortical?

Authors:  D F Benson
Journal:  Adv Neurol       Date:  1984

3.  Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease.

Authors:  B Pillon; B Dubois; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1986-09       Impact factor: 9.910

4.  Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors.

Authors:  F Boller; D Passafiume; N C Keefe; K Rogers; L Morrow; Y Kim
Journal:  Arch Neurol       Date:  1984-05

5.  Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease.

Authors:  F Girotti; F Carella; M P Grassi; P Soliveri; R Marano; T Caraceni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-06       Impact factor: 10.154

Review 6.  Subcortical dementia. Review of an emerging concept.

Authors:  J L Cummings; D F Benson
Journal:  Arch Neurol       Date:  1984-08

7.  Cognitive impairments in Parkinson's disease: distinguishing between effort-demanding and automatic cognitive processes.

Authors:  H Weingartner; S Burns; R Diebel; P A LeWitt
Journal:  Psychiatry Res       Date:  1984-03       Impact factor: 3.222

8.  Cognitive performance in early Parkinson's disease.

Authors:  M Hietanen; H Teräväinen
Journal:  Acta Neurol Scand       Date:  1986-02       Impact factor: 3.209

9.  Dementia in Parkinson's disease.

Authors:  S J Huber; E C Shuttleworth; G W Paulson
Journal:  Arch Neurol       Date:  1986-10

10.  Altered serotonin metabolism in depressed patients with parkinson's disease.

Authors:  R Mayeux; Y Stern; L Cote; J B Williams
Journal:  Neurology       Date:  1984-05       Impact factor: 9.910

View more
  2 in total

1.  Cognitive functioning after subthalamic nucleotomy for refractory Parkinson's disease.

Authors:  R J McCarter; N H Walton; A F Rowan; S S Gill; M Palomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-07       Impact factor: 10.154

Review 2.  Posteroventral medial pallidotomy in Parkinson's disease.

Authors:  A E Lang; J Duff; J A Saint-Cyr; L Trepanier; R E Gross; W Lombardi; E Montgomery; W Hutchinson; A M Lozano
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.